62 results match your criteria conjunction cll

Morphological and Molecular Study of Hybrid Oncocytic/Chromophobe Tumor of the Kidney Associated with Sporadic Renal Oncocytosis and Chronic B-Cell Lymphocytic Leukemia: The Possible Contribution of Lymphoma to Renal Oncocytosis.

Pathobiology 2021 Apr 21:1-10. Epub 2021 Apr 21.

Pathology, University Hospital Virgen Macarena, University of Seville, Sevilla, Spain.

Hybrid oncocytic/chromophobe tumor (HOCT) of the kidney arising from a precursor oncocytosis not associated with the Birt-Hogg-Dubé (BHD) syndrome is an unusual and highly interesting neoplasm. Immunohistochemical and molecular findings suggest that HOCT is an entity distinct from both oncocytoma and chromophobe carcinoma. Although uncertainty persists regarding the factors predisposing to the development of HOCT, experimental findings suggest that it may arise due to the effect of toxins or in association with chronic kidney failure. Read More

View Article and Full-Text PDF


Georgian Med News 2020 Nov(308):118-123

1Iv. Javakhishvili Tbilisi State University, Division of Immunology and Microbiology, Tbilisi, Georgia; 4University of Westminster, London, UK.

Chronic lymphocytic leukemia (CLL) is the most common adult leukaemia in the US and in Europe, including Georgia. CLL presents with clonal expansion and accumulation of CD5+CD19+CD23+ cells in peripheral lymphoid organs and tissues and in bone marrow. The disease remains incurable, albeit there are new molecular and immunotherapy methods currently available, which, in conjunction with chemotherapy, lead to the "precision therapy" approach. Read More

View Article and Full-Text PDF
November 2020

The up-to-date role of biologics for the treatment of chronic lymphocytic leukemia.

Expert Opin Biol Ther 2020 07 3;20(7):799-812. Epub 2020 Mar 3.

Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital , Lodz, Poland.

Introduction: Chronic lymphocytic leukemia (CLL) is a genetically complex disease that affects a heterogeneous patient population. Therapeutic armamentarium of CLL has changed recently following the introduction of novel active agents.

Areas Covered: This review presents the current state of knowledge about biologic drugs used in the treatment of patients with CLL. Read More

View Article and Full-Text PDF

Insight into genetic predisposition to chronic lymphocytic leukemia from integrative epigenomics.

Nat Commun 2019 08 9;10(1):3615. Epub 2019 Aug 9.

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036, Barcelona, Spain.

Genome-wide association studies have provided evidence for inherited genetic predisposition to chronic lymphocytic leukemia (CLL). To gain insight into the mechanisms underlying CLL risk we analyze chromatin accessibility, active regulatory elements marked by H3K27ac, and DNA methylation at 42 risk loci in up to 486 primary CLLs. We identify that risk loci are significantly enriched for active chromatin in CLL with evidence of being CLL-specific or differentially regulated in normal B-cell development. Read More

View Article and Full-Text PDF

Chromosomal microarray analysis is superior in identifying cryptic aberrations in patients with acute lymphoblastic leukemia at diagnosis/relapse as a single assay.

Int J Lab Hematol 2019 Aug 21;41(4):561-571. Epub 2019 May 21.

Cytogenetics Laboratory, Department of Molecular Pathology, Division of Pathology, Singapore General Hospital, Singapore, Singapore.

Introduction: Conventional cytogenetics (CC) is important in diagnosis, therapy, monitoring of post-transplant bone marrow, and prognosis assessment of acute lymphoblastic leukemia (ALL). However, due to the nature of ALL, CC often encounters difficulties of complex karyotype, poor chromosome morphology, low mitotic index, or normal cells dividing only. In contrast, chromosomal microarray analysis (CMA) showed a specificity >99% and a sensitivity of 100% in chronic lymphocytic leukemia (CLL) patients. Read More

View Article and Full-Text PDF

Genomic instability in a chronic lymphocytic leukemia patient with mono-allelic deletion of the and genes.

Mol Cytogenet 2019 31;12. Epub 2019 Jan 31.

2División de Genética, Centro de investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, CIBO-IMSS, Guadalajara, Jalisco Mexico.

Background: The most frequent cytogenetic abnormality detected in chronic lymphocytic leukemia (CLL) patients is the presence of a deletion within the chromosome band 13q14. Deletions can be heterogeneous in size, generally encompassing the and genes (minimal deleted region), but at times also including the gene. The latter, larger type of deletions are associated with worse prognosis. Read More

View Article and Full-Text PDF
January 2019

Synchronous Diagnosis of Acute Myeloid Leukemia with inv(16)(p13q22) and Chronic Lymphocytic Leukemia: A Case Report and Review of the Literature.

Ann Clin Lab Sci 2018 Nov;48(6):790-796

Department of Pathology and Laboratory Medicine, Western Connecticut Health Network, Danbury, CT, USA.

The occurrence of acute myeloid leukemia (AML) with chronic lymphocytic leukemia (CLL) is rare. Most cases of hematologic malignancies such as AML occurring in patients with pre-existing CLL are therapy-related. In this report, we describe a 65-year-old male with no past history of a hematolymphoid malignancy, who presented with abdominal pain. Read More

View Article and Full-Text PDF
November 2018

Comparison of Diagnostic Yield of a FISH Panel Against Conventional Cytogenetic Studies for Hematological Malignancies: A South Indian Referral Laboratory Analysis Of 201 Cases

Asian Pac J Cancer Prev 2017 Dec 29;18(12):3457-3464. Epub 2017 Dec 29.

Department of Cytogenetics, Anand Diagnostic Laboratory, Bangalore, India. Email:

Objectives: Genetic markers are crucial fort diagnostic and prognostic investigation of hematological malignancies (HM). The conventional cytogenetic study (CCS) has been the gold standard for more than five decades. However, FISH (Fluorescence in Situ Hybridization) testing has become a popular modality owing to its targeted approach and the ability to detect abnormalities in non-mitotic cells. Read More

View Article and Full-Text PDF
December 2017

International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high- and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia.

Qual Life Res 2018 02 10;27(2):333-345. Epub 2017 Nov 10.

Health Outcomes Research Unit, Italian Group for Adult Hematologic Diseases (GIMEMA) Data Centre, Rome, Italy.

Purpose: This paper describes the international, cross-cultural development of four disease-specific EORTC QoL questionnaires, to supplement the EORTC QLQ-C30, for patients with Hodgkin lymphoma (HL), high- or low-grade non-Hodgkin lymphoma (HG/LG-NHL), and CLL.

Methods: Questionnaire development was conducted according to guidelines from the EORTC Quality of Life Group. Phase I comprised generation of QoL issues relevant to patients. Read More

View Article and Full-Text PDF
February 2018


Georgian Med News 2017 Sep(270):88-93

Iv. Javakhishvili Tbilisi State University; Institute of Haematology and Blood Transfusiology, Tbilisi, Georgia; University of Westminster, London, UK.

Chronic lymphocytic leukaemia (CLL) is a lymphoproliferative disease characterised by accumulation of monoclonal CD19+CD5+CD23+ lymphocytes in the peripheral blood and bone marrow. CLL is the most common type of the adult leukemia in the Western world. The disease is incurable, albeit there are new molecular and immunotherapy methods currently available in conjunction with chemotherapy, leading to the "precision therapy". Read More

View Article and Full-Text PDF
September 2017

Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia.

Expert Opin Investig Drugs 2017 Nov 3;26(11):1249-1265. Epub 2017 Oct 3.

b Department of Hematology , Medical University of Lodz , Lodz , Poland.

Introduction: Over the last few years, several new synthetic drugs, particularly Bruton's tyrosine kinase (BTK), phosphatidylinositol 3-kinase (PI3K) and BCL-2 inhibitors have been developed and investigated in chronic lymphocytic leukemia (CLL). Areas covered: This review highlights key aspects of BTK, PI3K and BCL-2 inhibitors that are currently at various stages of preclinical and clinical development in CLL. A literature review of the MEDLINE database for articles in English concerning CLL, B-cell receptor, BCL-2 antagonists, BTK inhibitors and PI3K inhibitors, was conducted via PubMed. Read More

View Article and Full-Text PDF
November 2017

Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia.

Nat Commun 2017 07 28;8(1):153. Epub 2017 Jul 28.

Clinic I of Internal Medicine, University Hospital of Cologne, Cologne, 50931, Germany.

Chronic lymphocytic leukemia (CLL) remains an incurable disease. Two recurrent cytogenetic aberrations, namely del(17p), affecting TP53, and del(11q), affecting ATM, are associated with resistance against genotoxic chemotherapy (del17p) and poor outcome (del11q and del17p). Both del(17p) and del(11q) are also associated with inferior outcome to the novel targeted agents, such as the BTK inhibitor ibrutinib. Read More

View Article and Full-Text PDF

Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib.

Br J Haematol 2017 07 10;178(2):286-291. Epub 2017 Apr 10.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Bleeding events have been observed among a subgroup of chronic lymphocytic leukaemia (CLL) patients treated with ibrutinib. We analysed data from two studies of single-agent ibrutinib to better characterize bleeding events and pattern of anticoagulation and antiplatelet use. Among 327 ibrutinib-treated patients, concomitant anticoagulation (11%) or antiplatelet use (34%) was common, but major bleeding was infrequent (2%). Read More

View Article and Full-Text PDF

Long-Term Response and Possible Cure of Patients With B-Cell Malignancies With Dose-Escalated Rituximab.

J Investig Med High Impact Case Rep 2017 Jan-Mar;5(1):2324709617691307. Epub 2017 Feb 1.

British Hospital, Montevideo, Uruguay.

Rituximab (R), a chimeric monoclonal antibody targeting CD20 antigen on B-cells, has become a standard of care in the treatment of B-cell malignancies, most often in conjunction with cytotoxic chemotherapy. Activity has been demonstrated in many subtypes of B-cell lymphoma, including diffuse large cell lymphoma, follicular lymphoma (FL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), lymphocyte-predominant Hodgkin lymphoma, and Waldenström macroglobulinemia (WM). Additionally, dose escalation of R as a single agent has demonstrated improved activity in previously treated/poor prognosis CLL. Read More

View Article and Full-Text PDF
February 2017

Beetroot-Carrot Juice Intake either Alone or in Combination with Antileukemic Drug 'Chlorambucil' As A Potential Treatment for Chronic Lymphocytic Leukemia.

Open Access Maced J Med Sci 2015 Jun 2;3(2):331-6. Epub 2015 Jun 2.

National Research Centre, Nutrition and Food Science Department, El Buhouth St., Dokki, Cairo 12311, Egypt.

Chronic lymphocytic leukemia (CLL) is one of the chronic lymphoproliferative disorders (lymphoid neoplasms). It is characterized by a progressive accumulation of functionally incompetent lymphocytes. Patients with leukemia often seek unconventional treatments not prescribed by hematologist in order to improve their cancer treatment outcome or to manage symptoms. Read More

View Article and Full-Text PDF

The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.

Blood 2016 06 11;127(25):3215-24. Epub 2016 Apr 11.

Cancer and Haematology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia; Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, VIC, Australia; Department of Clinical Hematology and Bone Marrow Transplantation, The Royal Melbourne Hospital, Parkville, VIC, Australia;

BCL2 blunts activation of the mitochondrial pathway to apoptosis, and high-level expression is required for chronic lymphocytic leukemia (CLL) survival. Venetoclax (ABT-199) is a small-molecule selective inhibitor of BCL2 currently in clinical trials for CLL and other malignancies. In conjunction with the phase 1 first-in-human clinical trial of venetoclax in patients with relapsed or refractory CLL (M12-175), we investigated the mechanism of action of venetoclax in vivo, explored whether in vitro sensitivity assays or BH3 profiling correlated with in vivo responses in patients, and determined whether loss of TP53 function affected responses in vitro and in vivo. Read More

View Article and Full-Text PDF

Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study.

Clin Cancer Res 2016 Apr 9;22(7):1572-82. Epub 2015 Dec 9.

Hematology Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland.

Purpose: Chronic lymphocytic leukemia (CLL) cells depend on microenvironmental interactions for proliferation and survival that are at least partially mediated through B-cell receptor (BCR) signaling. Ibrutinib, a Bruton tyrosine kinase inhibitor, disrupts BCR signaling and leads to the egress of tumor cells from the microenvironment. Although the on-target effects on CLL cells are well defined, the impact on the microenvironment is less well studied. Read More

View Article and Full-Text PDF

Emerging immunological drugs for chronic lymphocytic leukemia.

Expert Opin Emerg Drugs 2015 Sep 11;20(3):423-47. Epub 2015 Jul 11.

a Medical University of Lodz, Departments of Experimental Hematology and Hematology, Copernicus Memorial Hospital , 93-510 Lodz, Ul. Ciolkowskiego 2, Poland +48 42 689 51 91 ; +48 42 689 51 92 ;

Introduction: Over the last few years, several new immunological drugs, particularly monoclonal antibodies (mAbs), immunomodulatory drugs and B-cell receptor (BCR) pathway inhibitors have been developed and investigated in chronic lymphocytic leukemia (CLL). This article summarizes recent discoveries regarding their mechanism of action, pharmacological properties, clinical activity and toxicity, as well as the emerging role of these agents in CLL.

Areas Covered: A literature review of mAbs, BCR pathway inhibitors and immunomodulating drugs was conducted of the MEDLINE database via PubMed for articles in English. Read More

View Article and Full-Text PDF
September 2015

Multilevel BCR signals toward CLL.

Blood 2015 Mar;125(10):1510-2


In this issue of Blood, Iacovelli et al provide the first in vivo experimental evidence on the proleukemogenic relevance of autonomous (exo-antigen–independent) B-cell receptor (BCR) stimulation in conjunction with ligand (autoantigen)- mediated BCR signaling in chronic lymphocytic leukemia (CLL). Read More

View Article and Full-Text PDF

Expanded CD8+ T cells of murine and human CLL are driven into a senescent KLRG1+ effector memory phenotype.

Cancer Immunol Immunother 2013 Nov;62(11):1697-1709

Altered numbers and functions of T cells have previously been demonstrated in chronic lymphocytic leukemia (CLL) patients. However, dynamics and specific T-cell subset alterations have not been studied in great detail. Therefore, we studied CLL blood lymphocyte subsets of individual patients in a longitudinal manner. Read More

View Article and Full-Text PDF
November 2013

Isolation and analysis of linker histones across cellular compartments.

J Proteomics 2013 Oct 5;91:595-604. Epub 2013 Sep 5.

Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, OH, USA; Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.

Unlabelled: Analysis of histones, especially histone H1, is severely limited by immunological reagent availability. This paper describes the application of cellular fractionation with LC-MS for profiling histones in the cytosol and upon chromatin. First, we show that linker histones enriched by cellular fractionation gives less nuclear contamination and higher histone content than when prepared by nuclei isolation. Read More

View Article and Full-Text PDF
October 2013

Complexation behavior of two-coordinated carbon compounds containing fluorenyl ligands.

Dalton Trans 2013 Oct 3;42(37):13349-56. Epub 2013 Jun 3.

Department of Chemistry, University of Stellenbosch, Private Bag X1, Matieland, Stellenbosch, South Africa.

DFT calculations using BP86 in conjunction with the SVP and TZVPP basis sets as well as ab initio calculations at SCS-MP2 have been carried out for six dicoordinated carbon molecules CLL' where L is a fluorenyl carbene while L' is a phosphine PH3 (1) or PPh3 (2) or a carbene, i.e. NHCMe (3), benzannulated NHCMe (4), cycloheptatrienylidene (5) and benzannulated cycloheptatrienylidene (6). Read More

View Article and Full-Text PDF
October 2013

Ca2+/calmodulin-dependent kinase II contributes to inhibitor of nuclear factor-kappa B kinase complex activation in Helicobacter pylori infection.

Int J Cancer 2013 Sep 29;133(6):1507-12. Epub 2013 Mar 29.

Institute of Experimental Internal Medicine, Otto von Guericke University, Leipziger Str. 44, 39120, Magdeburg, Germany.

Helicobacter pylori, a class I carcinogen, induces a proinflammatory response by activating the transcription factor nuclear factor-kappa B (NF-κB) in gastric epithelial cells. This inflammatory condition could lead to chronic gastritis, which is epidemiologically and biologically linked to the development of gastric cancer. So far, there exists no clear knowledge on how H. Read More

View Article and Full-Text PDF
September 2013

Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders.

Expert Opin Investig Drugs 2012 Jul 22;21(7):921-47. Epub 2012 May 22.

Medical University of Lodz, Department of Hematology, Lodz, Poland.

Introduction: In the last few years, several tyrosine kinase inhibitors (TKIs) have been synthesized and become available for preclinical studies and clinical trials. This article summarizes recent achievements in the mechanism of action, pharmacological properties, and clinical activity and toxicity, as well as the emerging role of TKIs in lymphoid malignancies, allergic diseases, and autoimmune disorders.

Areas Covered: A literature review was conducted of the MEDLINE database PubMed for articles in English. Read More

View Article and Full-Text PDF

Rituximab for chronic lymphocytic leukemia.

Tadeusz Robak

Expert Opin Biol Ther 2012 Apr 28;12(4):503-15. Epub 2012 Feb 28.

Medical University of Lodz, Lodz, Poland.

Introduction: Rituximab is a high-affinity chimeric mouse anti-CD20 monoclonal antibody, currently used for the treatment of non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL) and autoimmune disorders.

Areas Covered: This article summarizes recent achievements in the clinical activity and toxicity of rituximab in the treatment of patients with CLL. A literature search was conducted of the PubMed MEDLINE database for articles in English. Read More

View Article and Full-Text PDF

Can ex vivo evaluation (testing) predict the sensitivity of CLL cells to therapy with purine analogs in conjunction with an alkylating agent? A comparison of in vivo and ex vivo responses to treatment.

Med Oncol 2012 Sep 16;29(3):2111-26. Epub 2011 Nov 16.

Department of Cytobiochemistry, University of Łódz, Pomorska 141/143, 90-236 Łódz, Poland.

Malfunctions in the regulation of apoptosis cause the accumulation of malignant, long-lived B CD19+/CD5+ cells in chronic lymphocytic leukemia (CLL). The primary goal in CLL therapy is to overcome resistance to apoptosis and efficiently trigger programmed cell death in leukemic cells. This study demonstrated that the in vivo responses of malignant cells from CLL patients after administration of purine analogs (cladribine/fludarabine) with cyclophosphamide vary significantly. Read More

View Article and Full-Text PDF
September 2012

Characteristic CD103 and CD123 expression pattern defines hairy cell leukemia: usefulness of CD123 and CD103 in the diagnosis of mature B-cell lymphoproliferative disorders.

Am J Clin Pathol 2011 Oct;136(4):625-30

National Cancer Institute, 10 Center Drive, Bethesda, MD 20892, USA.

By using flow cytometry, we studied CD103 and CD123 expression by the malignant cells in 300 B-cell lymphoproliferative disorder (BC-LPD) cases, including 114 hairy cell leukemia (HCL), 20 HCL variant (HCLv), 9 splenic marginal zone lymphoma (SMZL; in 5, only CD103 was evaluated), 133 chronic lymphocytic leukemia (CLL), 3 follicular lymphoma (FL), and 21 mantle cell lymphoma (MCL). All HCLs expressed uniform CD103 and bright CD123. Among the 20 HCLv cases, 20 (100%) were CD103+ and 8 (40%) were CD123+ (partial or dim). Read More

View Article and Full-Text PDF
October 2011

Primary cutaneous follicle center lymphoma in the setting of chronic lymphocytic leukemia.

Indian J Dermatol Venereol Leprol 2011 May-Jun;77(3):314-7

Dermatopathology Section, Boston University School of Medicine, Boston, Massachusetts 02118, USA.

Primary cutaneous malignancies arising in association with chronic lymphocytic leukemia (CLL) are notable for their atypical clinical and histological presentation. We report a 69-year-old man with a 17-year history of CLL who presented for evaluation of a well-defined red to violaceous nodule with a central depressed scar on the left lower extremity. Microscopic examination of a punch biopsy revealed an infiltrate of predominantly small lymphocytes with scattered large, atypical epithelioid cells. Read More

View Article and Full-Text PDF

The JAK3-selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: potential for reversal of cytoprotection by the microenvironment.

Blood 2010 Nov 17;116(22):4569-77. Epub 2010 Aug 17.

Department of Hematology, Cancer Institute, University College Medical School, London, UK.

Extensive evidence suggests that the malignant cells of chronic lymphocytic leukemia (CLL) patients are in close contact with activated T lymphocytes, which secrete a range of cytoprotective cytokines including interleukin-4 (IL-4). IL-4 induced the rapid phosphorylation and activation of the signal transducer and activator of transcription 6 transcription factor in CLL cells in vitro. Longer incubation with IL-4 resulted in up-regulation of the antiapoptotic proteins, Mcl-1 and Bcl-X(L). Read More

View Article and Full-Text PDF
November 2010

Telomere dysfunction-induced foci arise with the onset of telomeric deletions and complex chromosomal aberrations in resistant chronic lymphocytic leukemia cells.

Blood 2010 Jul 27;116(2):239-49. Epub 2010 Apr 27.

Laboratoire d'OncoHématologie, Institut de Radiobiologie Cellulaire et Moléculaire, Direction des Sciences du Vivant, Commissariat à l'Energie Atomique, 18 Avenue du Panorama, Fontenay aux Roses, France.

In somatic cells, eroded telomeres can induce DNA double-strand break signaling, leading to a form of replicative senescence or apoptosis, both of which are barriers to tumorigenesis. However, cancer cells might display telomere dysfunctions which in conjunction with defects in DNA repair and apoptosis, enables them to circumvent these pathways. Chronic lymphocytic leukemia (CLL) cells exhibit telomere dysfunction, and a subset of these cells are resistant to DNA damage-induced apoptosis and display short telomeres. Read More

View Article and Full-Text PDF